Crohn's Disease - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：391頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Crohn's Disease - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Crohn's Disease - Pipeline Review, H1 2014’, provides an overview of the Crohn's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Crohn's Disease - Pipeline Review, H1 2014’, provides an overview of the Crohn's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Crohn's Disease Overview 13
Therapeutics Development 14
Pipeline Products for Crohn's Disease - Overview 14
Pipeline Products for Crohn's Disease - Comparative Analysis 15
Crohn's Disease - Therapeutics under Development by Companies 16
Crohn's Disease - Therapeutics under Investigation by Universities/Institutes 23
Crohn's Disease - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Crohn's Disease - Products under Development by Companies 28
Crohn's Disease - Products under Investigation by Universities/Institutes 35
Crohn's Disease - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Johnson & Johnson 37
Boehringer Ingelheim GmbH 38
Osiris Therapeutics, Inc. 39
Amgen Inc. 40
Sanofi 41
AstraZeneca PLC 42
Eli Lilly and Company 43
Inovio Pharmaceuticals, Inc. 44
Gilead Sciences, Inc. 45
Daiichi Sankyo Company, Limited 46
AbGenomics International, Inc. 47
Novo Nordisk A/S 48
Takeda Pharmaceutical Company Limited 49
BioLineRx, Ltd. 50
Celltrion, Inc. 51
Sylentis S.A. 52
Biocon Limited 53
Eisai Co., Ltd. 54
Pfizer Inc. 55
Teva Pharmaceutical Industries Limited 56
Sandoz Inc. 57
Celgene Corporation 58
Toray Industries, Inc. 59
4SC AG 60
iCo Therapeutics Inc. 61
Enzo Biochem, Inc. 62
NPS Pharmaceuticals, Inc. 63
Soligenix, Inc. 64
Protalix BioTherapeutics, Inc. 65
ProMetic Life Sciences Inc. 66
Galapagos NV 67
CIMAB S.A. 68
Alba Therapeutics Corporation 69
Farmacija d.o.o. Tuzla 70
Pieris AG 71
Neovacs SA 72
Viropro Inc. 73
Oncodesign SA 74
Tillotts Pharma AG 75
Allozyne, Inc. 76
Zealand Pharma A/S 77
NovImmune SA 78
TxCell SA 79
Selexys Pharmaceuticals Corporation 80
Effimune SAS 81
ChemoCentryx, Inc. 82
Giuliani S.p.A. 83
Winston Pharmaceuticals, Inc. 84
S.L.A. Pharma AG 85
Medestea Research & Production S.p.A. 86
Stelic Institute & Co. 87
Janssen Research & Development, LLC 88
Antibe Therapeutics, Inc. 89
CLL Pharma 90
Amunix, Inc. 91
Protagonist Therapeutics Inc. 92
Alfa Wassermann S.p.A 93
Altheus Therapeutics, Inc. 94
Sigmoid Pharma Ltd. 95
Ampio Pharmaceuticals, Inc. 96
Advancell 97
Genor BioPharma Co., Ltd. 98
Aprogen, Inc. 99
RedHill Biopharma Ltd. 100
Selvita S.A 101
Ensemble Therapeutics Corporation 102
Inbiopro Solutions Pvt. Ltd. 103
Enlivex Therapeutics Ltd 104
Immune Response BioPharma, Inc. 105
Qu Biologics Inc. 106
Oncobiologics, Inc. 107
Curaxys, S.L. 108
Innovent Biologics, Inc. 109
AbbVie Inc. 110
Trino Therapeutics Ltd 111
Aniona ApS 112
ChironWells GmbH 113
Epirus Biopharmaceuticals, Inc. 114
AlphaMab Co., Ltd 115
Calypso Biotech SA 116
Pharmapraxis 117
GT Biologics Limited 118
Crohn's Disease - Therapeutics Assessment 119
Assessment by Monotherapy Products 119
Assessment by Combination Products 120
Assessment by Target 121
Assessment by Mechanism of Action 126
Assessment by Route of Administration 131
Assessment by Molecule Type 134
Drug Profiles 137
vedolizumab - Drug Profile 137
infliximab biosimilar - Drug Profile 139
infliximab biosimilar - Drug Profile 141
remestemcel-L - Drug Profile 142
vedolizumab - Drug Profile 144
adalimumab - Drug Profile 146
ustekinumab - Drug Profile 148
vercirnon sodium - Drug Profile 150
infliximab - Drug Profile 152
budesonide ER - Drug Profile 154
(rifabutin + clarithromycin + clofazimine) - Drug Profile 156
infliximab biosimilar - Drug Profile 158
adalimumab biosimilar - Drug Profile 159
rifaximin - Drug Profile 160
laquinimod sodium - Drug Profile 162
tofacitinib - Drug Profile 164
eldelumab - Drug Profile 168
cenplacel-L - Drug Profile 170
PF-04236921 - Drug Profile 172
teduglutide - Drug Profile 173
TNF-Kinoid - Drug Profile 175
AbGn-168H - Drug Profile 177
foralumab - Drug Profile 178
mercaptopurine - Drug Profile 179
adalimumab - Drug Profile 180
vidofludimus - Drug Profile 182
OvaSave - Drug Profile 186
GED-0301 - Drug Profile 187
zucapsaicin - Drug Profile 188
Alequel - Drug Profile 190
GLPG-0634 - Drug Profile 191
FFP-102 - Drug Profile 193
metronidazole - Drug Profile 194
mesalamine CR - Drug Profile 196
AMG-139 - Drug Profile 197
PF-00547659 - Drug Profile 199
AMG-181 - Drug Profile 201
TRK-170 - Drug Profile 203
NN-8828 - Drug Profile 204
BI-655066 - Drug Profile 206
naltrexone - Drug Profile 207
(metenkefalin + tridecactide) - Drug Profile 208
naltrexone - Drug Profile 209
SGX-203 - Drug Profile 210
(rifabutin + clarithromycin + clofazimine) - Drug Profile 211
E-6011 - Drug Profile 213
QBECO SSI - Drug Profile 214
Furestem-CD - Drug Profile 216
apremilast - Drug Profile 217
ZP-1848 - Drug Profile 219
larazotide acetate - Drug Profile 220
bertilimumab - Drug Profile 222
IR-777 - Drug Profile 224
infliximab biosimilar - Drug Profile 225
SAR-252067 - Drug Profile 226
Atrosab - Drug Profile 227
CyCron - Drug Profile 228
SYN-1002 - Drug Profile 229
Biologic for Crohns Disease - Drug Profile 230
infliximab biosimilar - Drug Profile 231
adalimumab biosimilar - Drug Profile 232
adalimumab biosimilar - Drug Profile 233
BL-5040 - Drug Profile 234
VGX-1027 - Drug Profile 235
SelK2-Anti-PSGL-1 - Drug Profile 236
MP-196 - Drug Profile 237
STNM-01 - Drug Profile 238
ApoCell - Drug Profile 239
PBI-1737 - Drug Profile 240
(mesalamine + N-acetylcysteine) - Drug Profile 241
AZ-17 - Drug Profile 243
adalimumab biosimilar - Drug Profile 244
Ampion - Drug Profile 245
etanercept biosimilar - Drug Profile 247
Leukothera - Drug Profile 248
ATB-429 - Drug Profile 249
Antibody to inhibit MMP for Immunology and Gastrointestinal diseases - Drug Profile 250
adalimumab biosimilar - Drug Profile 251
AMX-256 - Drug Profile 252
ANs-42 - Drug Profile 253
Interleukin-17 Antagonist - Drug Profile 254
NS-17546 - Drug Profile 255
PH-46A - Drug Profile 256
ITP-01 - Drug Profile 257
IAC VITA - Drug Profile 258
Interleukin-6 Disulfide Rich Peptides Antagonist Program - Drug Profile 260
adalimumab biosimilar - Drug Profile 261
adalimumab biosimilar - Drug Profile 262
Anti Metallothioneins Antibodies - Drug Profile 263
PH-44 - Drug Profile 264
PH-5 - Drug Profile 265
Recombinant Cholera Toxin-B - Drug Profile 266
Chimeric Anti-TNF Alpha Monoclonal Antibody - Drug Profile 267
CALY-001 - Drug Profile 268
adalimumab biosimilar - Drug Profile 269
Mesenchymal Stem Cells - Drug Profile 270
AB-0045 - Drug Profile 271
LBP-001 - Drug Profile 272
Alpha-Defensins - Drug Profile 273
NAT-100 - Drug Profile 274
SQ-641 - Drug Profile 275
Drug For Crohn's Disease And Ulcerative Colitis - Drug Profile 276
PRS-190 - Drug Profile 277
ONS-3015 - Drug Profile 278
Drug For Inflammatory Bowel Diseases - Drug Profile 279
SEL-212 - Drug Profile 280
IBI-303 - Drug Profile 281
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 282
infliximab biosimilar - Drug Profile 283
adalimumab biosimilar - Drug Profile 284
Receptor-interacting serine/threonine-protein kinase 2 Inhibitor - Drug Profile 285
Drug For Crohns Disease - Drug Profile 286
INV-88 - Drug Profile 287
JNJ-40346527 - Drug Profile 288
IBPM-005-IX - Drug Profile 289
IBPM-004-AM - Drug Profile 290
adalimumab biosimilar - Drug Profile 291
infliximab biosmiliar - Drug Profile 292
infliximab biosimilar - Drug Profile 293
adalimumab biosimilar - Drug Profile 294
Crohn's Disease - Recent Pipeline Updates 295
Crohn's Disease - Dormant Projects 370
Crohn's Disease - Discontinued Products 373
Crohn's Disease - Product Development Milestones 374
Featured News & Press Releases 374
Appendix 382
Methodology 382
Coverage 382
Secondary Research 382
Primary Research 382
Expert Panel Validation 382
Contact Us 383
Disclaimer 383
List of Tables
Number of Products under Development for Crohn's Disease, H1 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Development by Companies, H1 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Development, H1 2014 34
Comparative Analysis by Unknown Stage Development, H1 2014 35
Products under Development by Companies, H1 2014 36
Products under Development by Companies, H1 2014 (Contd..1) 37
Products under Development by Companies, H1 2014 (Contd..2) 38
Products under Development by Companies, H1 2014 (Contd..3) 39
Products under Development by Companies, H1 2014 (Contd..4) 40
Products under Development by Companies, H1 2014 (Contd..5) 41
Products under Development by Companies, H1 2014 (Contd..6) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Crohn's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Crohn's Disease - Pipeline by Johnson & Johnson, H1 2014 45
Crohn's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 46
Crohn's Disease - Pipeline by Osiris Therapeutics, Inc., H1 2014 47
Crohn's Disease - Pipeline by Amgen Inc., H1 2014 48
Crohn's Disease - Pipeline by Sanofi, H1 2014 49
Crohn's Disease - Pipeline by AstraZeneca PLC, H1 2014 50
Crohn's Disease - Pipeline by Eli Lilly and Company, H1 2014 51
Crohn's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 52
Crohn's Disease - Pipeline by Gilead Sciences, Inc., H1 2014 53
Crohn's Disease - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 54
Crohn's Disease - Pipeline by AbGenomics International, Inc., H1 2014 55
Crohn's Disease - Pipeline by Novo Nordisk A/S, H1 2014 56
Crohn's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 57
Crohn's Disease - Pipeline by BioLineRx, Ltd., H1 2014 58
Crohn's Disease - Pipeline by Celltrion, Inc., H1 2014 59
Crohn's Disease - Pipeline by Sylentis S.A., H1 2014 60
Crohn's Disease - Pipeline by Biocon Limited, H1 2014 61
Crohn's Disease - Pipeline by Eisai Co., Ltd., H1 2014 62
Crohn's Disease - Pipeline by Pfizer Inc., H1 2014 63
Crohn's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 64
Crohn's Disease - Pipeline by Sandoz Inc., H1 2014 65
Crohn's Disease - Pipeline by Celgene Corporation, H1 2014 66
Crohn's Disease - Pipeline by Toray Industries, Inc., H1 2014 67
Crohn's Disease - Pipeline by 4SC AG, H1 2014 68
Crohn's Disease - Pipeline by iCo Therapeutics Inc., H1 2014 69
Crohn's Disease - Pipeline by Enzo Biochem, Inc., H1 2014 70
Crohn's Disease - Pipeline by NPS Pharmaceuticals, Inc., H1 2014 71
Crohn's Disease - Pipeline by Soligenix, Inc., H1 2014 72
Crohn's Disease - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 73
Crohn's Disease - Pipeline by ProMetic Life Sciences Inc., H1 2014 74
Crohn's Disease - Pipeline by Galapagos NV, H1 2014 75
Crohn's Disease - Pipeline by CIMAB S.A., H1 2014 76
Crohn's Disease - Pipeline by Alba Therapeutics Corporation, H1 2014 77
Crohn's Disease - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 78
Crohn's Disease - Pipeline by Pieris AG, H1 2014 79
Crohn's Disease - Pipeline by Neovacs SA, H1 2014 80
Crohn's Disease - Pipeline by Viropro Inc., H1 2014 81
Crohn's Disease - Pipeline by Oncodesign SA, H1 2014 82
Crohn's Disease - Pipeline by Tillotts Pharma AG, H1 2014 83
Crohn's Disease - Pipeline by Allozyne, Inc., H1 2014 84
Crohn's Disease - Pipeline by Zealand Pharma A/S, H1 2014 85
Crohn's Disease - Pipeline by NovImmune SA, H1 2014 86
Crohn's Disease - Pipeline by TxCell SA, H1 2014 87
Crohn's Disease - Pipeline by Selexys Pharmaceuticals Corporation, H1 2014 88
Crohn's Disease - Pipeline by Effimune SAS, H1 2014 89
Crohn's Disease - Pipeline by ChemoCentryx, Inc., H1 2014 90
Crohn's Disease - Pipeline by Giuliani S.p.A., H1 2014 91
Crohn's Disease - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 92
Crohn's Disease - Pipeline by S.L.A. Pharma AG, H1 2014 93
Crohn's Disease - Pipeline by Medestea Research & Production S.p.A., H1 2014 94
Crohn's Disease - Pipeline by Stelic Institute & Co., H1 2014 95
Crohn's Disease - Pipeline by Janssen Research & Development, LLC, H1 2014 96
Crohn's Disease - Pipeline by Antibe Therapeutics, Inc., H1 2014 97
Crohn's Disease - Pipeline by CLL Pharma, H1 2014 98
Crohn's Disease - Pipeline by Amunix, Inc., H1 2014 99
Crohn's Disease - Pipeline by Protagonist Therapeutics Inc., H1 2014 100
Crohn's Disease - Pipeline by Alfa Wassermann S.p.A., H1 2014 101
Crohn's Disease - Pipeline by Altheus Therapeutics, Inc., H1 2014 102
Crohn's Disease - Pipeline by Sigmoid Pharma Ltd., H1 2014 103
Crohn's Disease - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 104
Crohn's Disease - Pipeline by Advancell, H1 2014 105
Crohn's Disease - Pipeline by Genor BioPharma Co., Ltd., H1 2014 106
Crohn's Disease - Pipeline by Aprogen, Inc., H1 2014 107
Crohn's Disease - Pipeline by RedHill Biopharma Ltd., H1 2014 108
Crohn's Disease - Pipeline by Selvita S.A, H1 2014 109
Crohn's Disease - Pipeline by Ensemble Therapeutics Corporation, H1 2014 110
Crohn's Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 111
Crohn's Disease - Pipeline by Enlivex Therapeutics Ltd, H1 2014 112
Crohn's Disease - Pipeline by Immune Response BioPharma, Inc., H1 2014 113
Crohn's Disease - Pipeline by Qu Biologics Inc., H1 2014 114
Crohn's Disease - Pipeline by Oncobiologics, Inc., H1 2014 115
Crohn's Disease - Pipeline by Curaxys, S.L., H1 2014 116
Crohn's Disease - Pipeline by Innovent Biologics, Inc., H1 2014 117
Crohn's Disease - Pipeline by AbbVie Inc., H1 2014 118
Crohn's Disease - Pipeline by Trino Therapeutics Ltd, H1 2014 119
Crohn's Disease - Pipeline by Aniona ApS, H1 2014 120
Crohn's Disease - Pipeline by ChironWells GmbH, H1 2014 121
Crohn's Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 122
Crohn's Disease - Pipeline by AlphaMab Co., Ltd, H1 2014 123
Crohn's Disease - Pipeline by Calypso Biotech SA, H1 2014 124
Crohn's Disease - Pipeline by Pharmapraxis, H1 2014 125
Crohn's Disease - Pipeline by GT Biologics Limited, H1 2014 126
Assessment by Monotherapy Products, H1 2014 127
Assessment by Combination Products, H1 2014 128
Number of Products by Stage and Target, H1 2014 131
Number of Products by Stage and Mechanism of Action, H1 2014 136
Number of Products by Stage and Route of Administration, H1 2014 141
Number of Products by Stage and Molecule Type, H1 2014 144
Crohn's Disease Therapeutics - Recent Pipeline Updates, H1 2014 303
Crohn's Disease - Dormant Projects, H1 2014 378
Crohn's Disease - Discontinued Products, H1 2014 381
List of Figures
Number of Products under Development for Crohn's Disease, H1 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Products, H1 2014 34
Assessment by Monotherapy Products, H1 2014 127
Assessment by Combination Products, H1 2014 128
Number of Products by Top 10 Target, H1 2014 129
Number of Products by Stage and Top 10 Target, H1 2014 130
Number of Products by Top 10 Mechanism of Action, H1 2014 134
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 135
Number of Products by Top 10 Route of Administration, H1 2014 139
Number of Products by Stage and Top 10 Route of Administration, H1 2014 140
Number of Products by Top 10 Molecule Type, H1 2014 142
Number of Products by Stage and Top 10 Molecule Type, H1 2014 143
Table of Contents 2
List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Crohn's Disease Overview 13
Therapeutics Development 14
Pipeline Products for Crohn's Disease - Overview 14
Pipeline Products for Crohn's Disease - Comparative Analysis 15
Crohn's Disease - Therapeutics under Development by Companies 16
Crohn's Disease - Therapeutics under Investigation by Universities/Institutes 23
Crohn's Disease - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Crohn's Disease - Products under Development by Companies 28
Crohn's Disease - Products under Investigation by Universities/Institutes 35
Crohn's Disease - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Johnson & Johnson 37
Boehringer Ingelheim GmbH 38
Osiris Therapeutics, Inc. 39
Amgen Inc. 40
Sanofi 41
AstraZeneca PLC 42
Eli Lilly and Company 43
Inovio Pharmaceuticals, Inc. 44
Gilead Sciences, Inc. 45
Daiichi Sankyo Company, Limited 46
AbGenomics International, Inc. 47
Novo Nordisk A/S 48
Takeda Pharmaceutical Company Limited 49
BioLineRx, Ltd. 50
Celltrion, Inc. 51
Sylentis S.A. 52
Biocon Limited 53
Eisai Co., Ltd. 54
Pfizer Inc. 55
Teva Pharmaceutical Industries Limited 56
Sandoz Inc. 57
Celgene Corporation 58
Toray Industries, Inc. 59
4SC AG 60
iCo Therapeutics Inc. 61
Enzo Biochem, Inc. 62
NPS Pharmaceuticals, Inc. 63
Soligenix, Inc. 64
Protalix BioTherapeutics, Inc. 65
ProMetic Life Sciences Inc. 66
Galapagos NV 67
CIMAB S.A. 68
Alba Therapeutics Corporation 69
Farmacija d.o.o. Tuzla 70
Pieris AG 71
Neovacs SA 72
Viropro Inc. 73
Oncodesign SA 74
Tillotts Pharma AG 75
Allozyne, Inc. 76
Zealand Pharma A/S 77
NovImmune SA 78
TxCell SA 79
Selexys Pharmaceuticals Corporation 80
Effimune SAS 81
ChemoCentryx, Inc. 82
Giuliani S.p.A. 83
Winston Pharmaceuticals, Inc. 84
S.L.A. Pharma AG 85
Medestea Research & Production S.p.A. 86
Stelic Institute & Co. 87
Janssen Research & Development, LLC 88
Antibe Therapeutics, Inc. 89
CLL Pharma 90
Amunix, Inc. 91
Protagonist Therapeutics Inc. 92
Alfa Wassermann S.p.A 93
Altheus Therapeutics, Inc. 94
Sigmoid Pharma Ltd. 95
Ampio Pharmaceuticals, Inc. 96
Advancell 97
Genor BioPharma Co., Ltd. 98
Aprogen, Inc. 99
RedHill Biopharma Ltd. 100
Selvita S.A 101
Ensemble Therapeutics Corporation 102
Inbiopro Solutions Pvt. Ltd. 103
Enlivex Therapeutics Ltd 104
Immune Response BioPharma, Inc. 105
Qu Biologics Inc. 106
Oncobiologics, Inc. 107
Curaxys, S.L. 108
Innovent Biologics, Inc. 109
AbbVie Inc. 110
Trino Therapeutics Ltd 111
Aniona ApS 112
ChironWells GmbH 113
Epirus Biopharmaceuticals, Inc. 114
AlphaMab Co., Ltd 115
Calypso Biotech SA 116
Pharmapraxis 117
GT Biologics Limited 118
Crohn's Disease - Therapeutics Assessment 119
Assessment by Monotherapy Products 119
Assessment by Combination Products 120
Assessment by Target 121
Assessment by Mechanism of Action 126
Assessment by Route of Administration 131
Assessment by Molecule Type 134
Drug Profiles 137
vedolizumab - Drug Profile 137
infliximab biosimilar - Drug Profile 139
infliximab biosimilar - Drug Profile 141
remestemcel-L - Drug Profile 142
vedolizumab - Drug Profile 144
adalimumab - Drug Profile 146
ustekinumab - Drug Profile 148
vercirnon sodium - Drug Profile 150
infliximab - Drug Profile 152
budesonide ER - Drug Profile 154
(rifabutin + clarithromycin + clofazimine) - Drug Profile 156
infliximab biosimilar - Drug Profile 158
adalimumab biosimilar - Drug Profile 159
rifaximin - Drug Profile 160
laquinimod sodium - Drug Profile 162
tofacitinib - Drug Profile 164
eldelumab - Drug Profile 168
cenplacel-L - Drug Profile 170
PF-04236921 - Drug Profile 172
teduglutide - Drug Profile 173
TNF-Kinoid - Drug Profile 175
AbGn-168H - Drug Profile 177
foralumab - Drug Profile 178
mercaptopurine - Drug Profile 179
adalimumab - Drug Profile 180
vidofludimus - Drug Profile 182
OvaSave - Drug Profile 186
GED-0301 - Drug Profile 187
zucapsaicin - Drug Profile 188
Alequel - Drug Profile 190
GLPG-0634 - Drug Profile 191
FFP-102 - Drug Profile 193
metronidazole - Drug Profile 194
mesalamine CR - Drug Profile 196
AMG-139 - Drug Profile 197
PF-00547659 - Drug Profile 199
AMG-181 - Drug Profile 201
TRK-170 - Drug Profile 203
NN-8828 - Drug Profile 204
BI-655066 - Drug Profile 206
naltrexone - Drug Profile 207
(metenkefalin + tridecactide) - Drug Profile 208
naltrexone - Drug Profile 209
SGX-203 - Drug Profile 210
(rifabutin + clarithromycin + clofazimine) - Drug Profile 211
E-6011 - Drug Profile 213
QBECO SSI - Drug Profile 214
Furestem-CD - Drug Profile 216
apremilast - Drug Profile 217
ZP-1848 - Drug Profile 219
larazotide acetate - Drug Profile 220
bertilimumab - Drug Profile 222
IR-777 - Drug Profile 224
infliximab biosimilar - Drug Profile 225
SAR-252067 - Drug Profile 226
Atrosab - Drug Profile 227
CyCron - Drug Profile 228
SYN-1002 - Drug Profile 229
Biologic for Crohns Disease - Drug Profile 230
infliximab biosimilar - Drug Profile 231
adalimumab biosimilar - Drug Profile 232
adalimumab biosimilar - Drug Profile 233
BL-5040 - Drug Profile 234
VGX-1027 - Drug Profile 235
SelK2-Anti-PSGL-1 - Drug Profile 236
MP-196 - Drug Profile 237
STNM-01 - Drug Profile 238
ApoCell - Drug Profile 239
PBI-1737 - Drug Profile 240
(mesalamine + N-acetylcysteine) - Drug Profile 241
AZ-17 - Drug Profile 243
adalimumab biosimilar - Drug Profile 244
Ampion - Drug Profile 245
etanercept biosimilar - Drug Profile 247
Leukothera - Drug Profile 248
ATB-429 - Drug Profile 249
Antibody to inhibit MMP for Immunology and Gastrointestinal diseases - Drug Profile 250
adalimumab biosimilar - Drug Profile 251
AMX-256 - Drug Profile 252
ANs-42 - Drug Profile 253
Interleukin-17 Antagonist - Drug Profile 254
NS-17546 - Drug Profile 255
PH-46A - Drug Profile 256
ITP-01 - Drug Profile 257
IAC VITA - Drug Profile 258
Interleukin-6 Disulfide Rich Peptides Antagonist Program - Drug Profile 260
adalimumab biosimilar - Drug Profile 261
adalimumab biosimilar - Drug Profile 262
Anti Metallothioneins Antibodies - Drug Profile 263
PH-44 - Drug Profile 264
PH-5 - Drug Profile 265
Recombinant Cholera Toxin-B - Drug Profile 266
Chimeric Anti-TNF Alpha Monoclonal Antibody - Drug Profile 267
CALY-001 - Drug Profile 268
adalimumab biosimilar - Drug Profile 269
Mesenchymal Stem Cells - Drug Profile 270
AB-0045 - Drug Profile 271
LBP-001 - Drug Profile 272
Alpha-Defensins - Drug Profile 273
NAT-100 - Drug Profile 274
SQ-641 - Drug Profile 275
Drug For Crohn's Disease And Ulcerative Colitis - Drug Profile 276
PRS-190 - Drug Profile 277
ONS-3015 - Drug Profile 278
Drug For Inflammatory Bowel Diseases - Drug Profile 279
SEL-212 - Drug Profile 280
IBI-303 - Drug Profile 281
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 282
infliximab biosimilar - Drug Profile 283
adalimumab biosimilar - Drug Profile 284
Receptor-interacting serine/threonine-protein kinase 2 Inhibitor - Drug Profile 285
Drug For Crohns Disease - Drug Profile 286
INV-88 - Drug Profile 287
JNJ-40346527 - Drug Profile 288
IBPM-005-IX - Drug Profile 289
IBPM-004-AM - Drug Profile 290
adalimumab biosimilar - Drug Profile 291
infliximab biosmiliar - Drug Profile 292
infliximab biosimilar - Drug Profile 293
adalimumab biosimilar - Drug Profile 294
Crohn's Disease - Recent Pipeline Updates 295
Crohn's Disease - Dormant Projects 370
Crohn's Disease - Discontinued Products 373
Crohn's Disease - Product Development Milestones 374
Featured News & Press Releases 374
Appendix 382
Methodology 382
Coverage 382
Secondary Research 382
Primary Research 382
Expert Panel Validation 382
Contact Us 383
Disclaimer 383
List of Tables
Number of Products under Development for Crohn's Disease, H1 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Development by Companies, H1 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Development, H1 2014 34
Comparative Analysis by Unknown Stage Development, H1 2014 35
Products under Development by Companies, H1 2014 36
Products under Development by Companies, H1 2014 (Contd..1) 37
Products under Development by Companies, H1 2014 (Contd..2) 38
Products under Development by Companies, H1 2014 (Contd..3) 39
Products under Development by Companies, H1 2014 (Contd..4) 40
Products under Development by Companies, H1 2014 (Contd..5) 41
Products under Development by Companies, H1 2014 (Contd..6) 42
Products under Investigation by Universities/Institutes, H1 2014 43
Crohn's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Crohn's Disease - Pipeline by Johnson & Johnson, H1 2014 45
Crohn's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 46
Crohn's Disease - Pipeline by Osiris Therapeutics, Inc., H1 2014 47
Crohn's Disease - Pipeline by Amgen Inc., H1 2014 48
Crohn's Disease - Pipeline by Sanofi, H1 2014 49
Crohn's Disease - Pipeline by AstraZeneca PLC, H1 2014 50
Crohn's Disease - Pipeline by Eli Lilly and Company, H1 2014 51
Crohn's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 52
Crohn's Disease - Pipeline by Gilead Sciences, Inc., H1 2014 53
Crohn's Disease - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 54
Crohn's Disease - Pipeline by AbGenomics International, Inc., H1 2014 55
Crohn's Disease - Pipeline by Novo Nordisk A/S, H1 2014 56
Crohn's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 57
Crohn's Disease - Pipeline by BioLineRx, Ltd., H1 2014 58
Crohn's Disease - Pipeline by Celltrion, Inc., H1 2014 59
Crohn's Disease - Pipeline by Sylentis S.A., H1 2014 60
Crohn's Disease - Pipeline by Biocon Limited, H1 2014 61
Crohn's Disease - Pipeline by Eisai Co., Ltd., H1 2014 62
Crohn's Disease - Pipeline by Pfizer Inc., H1 2014 63
Crohn's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 64
Crohn's Disease - Pipeline by Sandoz Inc., H1 2014 65
Crohn's Disease - Pipeline by Celgene Corporation, H1 2014 66
Crohn's Disease - Pipeline by Toray Industries, Inc., H1 2014 67
Crohn's Disease - Pipeline by 4SC AG, H1 2014 68
Crohn's Disease - Pipeline by iCo Therapeutics Inc., H1 2014 69
Crohn's Disease - Pipeline by Enzo Biochem, Inc., H1 2014 70
Crohn's Disease - Pipeline by NPS Pharmaceuticals, Inc., H1 2014 71
Crohn's Disease - Pipeline by Soligenix, Inc., H1 2014 72
Crohn's Disease - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 73
Crohn's Disease - Pipeline by ProMetic Life Sciences Inc., H1 2014 74
Crohn's Disease - Pipeline by Galapagos NV, H1 2014 75
Crohn's Disease - Pipeline by CIMAB S.A., H1 2014 76
Crohn's Disease - Pipeline by Alba Therapeutics Corporation, H1 2014 77
Crohn's Disease - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 78
Crohn's Disease - Pipeline by Pieris AG, H1 2014 79
Crohn's Disease - Pipeline by Neovacs SA, H1 2014 80
Crohn's Disease - Pipeline by Viropro Inc., H1 2014 81
Crohn's Disease - Pipeline by Oncodesign SA, H1 2014 82
Crohn's Disease - Pipeline by Tillotts Pharma AG, H1 2014 83
Crohn's Disease - Pipeline by Allozyne, Inc., H1 2014 84
Crohn's Disease - Pipeline by Zealand Pharma A/S, H1 2014 85
Crohn's Disease - Pipeline by NovImmune SA, H1 2014 86
Crohn's Disease - Pipeline by TxCell SA, H1 2014 87
Crohn's Disease - Pipeline by Selexys Pharmaceuticals Corporation, H1 2014 88
Crohn's Disease - Pipeline by Effimune SAS, H1 2014 89
Crohn's Disease - Pipeline by ChemoCentryx, Inc., H1 2014 90
Crohn's Disease - Pipeline by Giuliani S.p.A., H1 2014 91
Crohn's Disease - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 92
Crohn's Disease - Pipeline by S.L.A. Pharma AG, H1 2014 93
Crohn's Disease - Pipeline by Medestea Research & Production S.p.A., H1 2014 94
Crohn's Disease - Pipeline by Stelic Institute & Co., H1 2014 95
Crohn's Disease - Pipeline by Janssen Research & Development, LLC, H1 2014 96
Crohn's Disease - Pipeline by Antibe Therapeutics, Inc., H1 2014 97
Crohn's Disease - Pipeline by CLL Pharma, H1 2014 98
Crohn's Disease - Pipeline by Amunix, Inc., H1 2014 99
Crohn's Disease - Pipeline by Protagonist Therapeutics Inc., H1 2014 100
Crohn's Disease - Pipeline by Alfa Wassermann S.p.A., H1 2014 101
Crohn's Disease - Pipeline by Altheus Therapeutics, Inc., H1 2014 102
Crohn's Disease - Pipeline by Sigmoid Pharma Ltd., H1 2014 103
Crohn's Disease - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 104
Crohn's Disease - Pipeline by Advancell, H1 2014 105
Crohn's Disease - Pipeline by Genor BioPharma Co., Ltd., H1 2014 106
Crohn's Disease - Pipeline by Aprogen, Inc., H1 2014 107
Crohn's Disease - Pipeline by RedHill Biopharma Ltd., H1 2014 108
Crohn's Disease - Pipeline by Selvita S.A, H1 2014 109
Crohn's Disease - Pipeline by Ensemble Therapeutics Corporation, H1 2014 110
Crohn's Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 111
Crohn's Disease - Pipeline by Enlivex Therapeutics Ltd, H1 2014 112
Crohn's Disease - Pipeline by Immune Response BioPharma, Inc., H1 2014 113
Crohn's Disease - Pipeline by Qu Biologics Inc., H1 2014 114
Crohn's Disease - Pipeline by Oncobiologics, Inc., H1 2014 115
Crohn's Disease - Pipeline by Curaxys, S.L., H1 2014 116
Crohn's Disease - Pipeline by Innovent Biologics, Inc., H1 2014 117
Crohn's Disease - Pipeline by AbbVie Inc., H1 2014 118
Crohn's Disease - Pipeline by Trino Therapeutics Ltd, H1 2014 119
Crohn's Disease - Pipeline by Aniona ApS, H1 2014 120
Crohn's Disease - Pipeline by ChironWells GmbH, H1 2014 121
Crohn's Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 122
Crohn's Disease - Pipeline by AlphaMab Co., Ltd, H1 2014 123
Crohn's Disease - Pipeline by Calypso Biotech SA, H1 2014 124
Crohn's Disease - Pipeline by Pharmapraxis, H1 2014 125
Crohn's Disease - Pipeline by GT Biologics Limited, H1 2014 126
Assessment by Monotherapy Products, H1 2014 127
Assessment by Combination Products, H1 2014 128
Number of Products by Stage and Target, H1 2014 131
Number of Products by Stage and Mechanism of Action, H1 2014 136
Number of Products by Stage and Route of Administration, H1 2014 141
Number of Products by Stage and Molecule Type, H1 2014 144
Crohn's Disease Therapeutics - Recent Pipeline Updates, H1 2014 303
Crohn's Disease - Dormant Projects, H1 2014 378
Crohn's Disease - Discontinued Products, H1 2014 381
List of Figures
Number of Products under Development for Crohn's Disease, H1 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Products, H1 2014 34
Assessment by Monotherapy Products, H1 2014 127
Assessment by Combination Products, H1 2014 128
Number of Products by Top 10 Target, H1 2014 129
Number of Products by Stage and Top 10 Target, H1 2014 130
Number of Products by Top 10 Mechanism of Action, H1 2014 134
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 135
Number of Products by Top 10 Route of Administration, H1 2014 139
Number of Products by Stage and Top 10 Route of Administration, H1 2014 140
Number of Products by Top 10 Molecule Type, H1 2014 142
Number of Products by Stage and Top 10 Molecule Type, H1 2014 143
